Merit CRO
Merit CRO is recorded as a service provider in 25 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 25 trials · Latest update first
Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)
Sponsor Dompe' Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Sponsor Eyepoint Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
Sponsor Eyepoint Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Azetukalner in Major Depressive Disorder
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 2, double-masked, randomized, multicenter, parallel group, placebo-controlled study to investigate the efficacy and safety of GAL-101, 2%, ophthalmic solution in patients with non-foveal geographic atrophy secondary to non-neovascular age-related macular degeneration: eDREAM study
Sponsor Galimedix Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Sponsor Dompe' Farmaceutici S.p.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients with Selected Advanced Solid Tumors
Sponsor ADC Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Enrollment was substantially below plan: 30 patients were enrolled globally versus approximately 132 planned.
- Part 1 enrolled 26 of 92 planned patients and Part 2 enrolled 4 of 40 planned patients; backfilling was not opened.
- The study operated at 13 sites: 4 in Spain, 2 in the United Kingdom, and 7 in the United States.
- Following the single response observed in cholangiocarcinoma during Part 1, Part 2 enrolled only patients with cholangiocarcinoma; no response was observed in Part 2.
These findings describe the trial, not the service provider’s performance or responsibility.
A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy with TTX-381 for the Ocular Manifestations Associated with Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease
Sponsor Tern Therapeutics LLC
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Study to Demonstrate Efficacy and Safety of DFL24498 Eye Drop Solution in Adult Participants with Atopic Keratoconjunctivitis (AKC)
Sponsor Dompe' Farmaceutici S.p.A.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
Sponsor UCB Biopharma
- Start (EU)
- Latest update
- Estimated end
A randomised, double-masked, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of oral BI 1815368 in participants with centre-involved diabetic macular edema for 48 weeks of treatment (THULITE)
Sponsor Boehringer Ingelheim International GmbH
- Start (EU)
- Latest update
- Estimated end
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ASCENT)
Sponsor Abbvie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Merit CRO?
The 2026-10-09 snapshot links Merit CRO to 25 distinct CTIS trials. Recorded services include Imaging Center, Opthalmologist - Central Reading, Central Ophthalmology Reader, Ophthalmologic assessment, among 18 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Merit CRO?
The most frequently recorded therapeutic areas are Ophthalmology, Psychiatry, Endocrinology, Neurology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Merit CRO conducted?
The linked trials record locations in 21 countries, including Germany, Spain, Italy, Poland, Czechia. These are trial locations, not confirmed office locations or countries where Merit CRO delivered services.
What can this page tell me about Merit CRO's trial experience?
Browse 25 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Merit CRO. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Merit CRO Inc.